PFS

1:34
Do CLL patients with mutated immunoglobulin receptors respond better to therapy?
Paolo Ghia
0:36
Do immunoglobulin receptor interactions play a role in CLL?
Paolo Ghia
1:33
What to look for in novel CLL therapies
Kostas Stamatopoulos
1:37
Which is the best combination therapy in relapsed and refractory multiple myeloma?
Meletios Dimopoulos
3:19
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
Nikhil Munshi
2:34
What’s next for rare myelomas?
Elena Zamagni
4:44
What are the advantages of multiple myeloma maintenance therapy?
Laurent Garderet
2:28
Is autologous stem cell transplantation still the backbone of multiple myeloma treatment?
Nicolaus Kröger
2:13
Reinforcing transplantation with consolidation therapy in Hodgkin lymphoma
Anna Sureda
2:36
What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?
Paul Richardson
4:05
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Ola Landgren
4:43
Immunotherapy highlights in multiple myeloma at ASH 2016
Niels van de Donk
2:11
Temsirolimus with BERT for the treatment of relapsed mantle cell and follicular lymphoma
Georg Hess
11:19
New endpoints in clinical trials to better serve patients
Elihu H. Estey
3:21
Current therapy for CLL and the new monoclonal antibody ofatumumab
Tadeusz Robak
4:09
Highlights from EHA 2016 press briefings: POLLUX and EURO-SKI trials and BiTE antibodies
Anton Hagenbeek
The content of VJHemOnc is intended for healthcare professionals